MERCK & CO., INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 125.2 USD | -0.13% |
|
-0.75% | +14.85% |
| Apr. 15 | Zacks Adjusts Price Target on Merck & Company to $132 From $128 | MT |
| Apr. 11 | Merck & Co Receives a Shareholder Proposal from The Bahnsen Family Trust | CI |
Presenter SpeechUnknown Attendee (Attendees)Okay. Cool. Hi. Thanks, everybody, and welcome. We...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:
- sale of pharmaceutical products (69.7%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;
- sale of vaccines (18%);
- sale of animal health products (9.4%);
- other (2.9%).
Net sales are distributed geographically as follows: the United States (45.9%), Europe/Middle East/Africa (24.5%), China (8.8%), Japan (6.1%), Asia/Pacific (6.1%), Latin America (4.3%) and other (4.3%).
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
125.2
USD
Average target price
137.2
USD
Spread / Average Target
+9.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.85% | 317B | |
| +27.97% | 672B | |
| +23.58% | 550B | |
| -7.02% | 351B | |
| +6.25% | 292B | |
| +2.96% | 211B | |
| -0.41% | 203B | |
| -10.02% | 194B | |
| -11.81% | 144B | |
| -8.80% | 141B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- Transcript : Merck & Co., Inc. Presents at 2020 HMG Live! New York Global Innovation Summit, Dec-03-2020
